USAN drug names under consideration


USAN Council's statement on the use of USAN as domain names is that a name published by the United States Adopted Names (USAN) Program in the USP Dictionary of USAN and International Nonproprietary Names, and on the United States Adopted Names website shall be the effective equivalent of an intellectual property right for the relevant entities.

Visit United States Adopted Names FAQ to learn more.

Comments or protests should be addressed to Stephanie Shubat, USAN program director, American Medical Association, 330 North Wabash Ave., Suite 39300, Chicago, Illinois 60611, or via email: [email protected]

In order to ensure your "under consideration" USAN domain name is available, you should consider purchasing the .com, .net and .org domain names of the USAN under consideration. The optimal time to do this is when you receive the letter from the USAN Program informing you of the USAN Council's naming decision.

The following names for the drugs described are "under consideration" by the USAN Council:

Avitotamig: Treatment of acute myeloid leukemia (AML)

Bexotegrast: Treatment of idiopathic pulmonary fibrosis (IPF) and of primary sclerosing cholangitis (PSC)  

Crelosidenib gentisate: Antineoplastic  

Forimtamig: Antineoplastic  

Lorundrostat: Treatment of aldosterone dependent cardiorenal conditions such as hypertension, chronic kidney disease and congestive heart failure  

Mocravimod: For use in combination with allogeneic hematopoeitic cell transplantation as postremission therapy for hematological malignancies

Nomlabofusp: Treatment of Friedreich’s ataxia (FRDA)

Obeldesivir: Treatment of SARS-CoV-2 infection

Osemitamab: Treatment of Solid tumors

Polzastobart: Antineoplastic

Revumenib: Antineoplastic

Rilparencel: Treatment of chronic kidney disease (CKD)

Tindupepimut: Antineoplastic

Zocaglusagene nuzaparvovec: Treatment of Pompe disease

Anselamimab: Treatment of light chain amyloid fibril  

Arlocabtagene autoleucel: Antineoplastic

Crelosidenib: Antineoplastic  

Dalmitamig: Antineoplastic, treatment of solid tumors  

Ficerafusp alfa: Antineoplastic

Fidrisertib: Treatment of fibrodysplasia ossificans progressiva (FOP)

Ibuzatrelvir: Treatment of COVID-19

Lepodisiran: To reduce the risk of major cardiovascular events (MACE) in patients with or at high risk of ASCVD and high levels of Lp(a)

Noraramtide: Treatment of Multiple Myeloma

Nibrozetone: Antiviral, treatment of SARS-CoV-2 infection

Nisostirotide: Treatment of diabetes and/or obesity

Plozasiran: Treatment of mixed dyslipedemia, severe hypertriglyceridemia and familial chylomicronemia syndrome (FCS) 

Sefaxersen: Treatment of geographic atrophy (GA) associated with age-related macular degeneration. and treatment of Immunoglobulin A (IgA) nephropathy

Soquelitinib: Treatment of patients with lymphomas and autoimmune disease

Spunoleucel: Treatment of respiratory viral infections

Tigozertinib: Antineoplastic

Vanzacaftor: Treatment of cystic fibrosis

Adakitug: Antineoplastic 

Admilparant: Treatment of patients with idiopathic pulmonary fibrosis (IPF) and progressive fibrosing interstitial lung disease (PF-ILD)   

Ezobresib: Treatment of Stargardt Disease, inherited retinal dystrophies, and age-related macular degeneration, including geographic atrophy (inhibits vitamin A dimerization in the retina through a kinetic isotope effect)  

Gildeuretinol: Treatment of Stargardt Disease, inherited retinal dystrophies, and age-related macular degeneration, including geographic atrophy (inhibits vitamin A dimerization in the retina through a kinetic isotope effect)  

Imdusiran: Treatment of chronic hepatitis B viral (HBV) infection

Lefelsiran: Treatment of alcohol use disorder (AUD)  

Lomedeucitinib: Antineoplastic

Lunresertib: Treatment of Psoriasis

Navenibart: Treatment of hereditary angioedema (HAE) in adults and pediatric patients  

Olgotrelvir: Antiviral, treatment of SARS-CoV-2 infection

Solbinsiran: Treatment for dyslipidemia in patients with or at high risk of atherosclerotic cardiovascular disease, to reduce the risk of major adverse cardiovascular events

Stannic protoporfin: Prevention of organ damage 

Zodasiran: Treatment of mixed dyslipidemia and homozygous familial hypercholesterolemia (HoFH)

Zopocianine: Intraoperative imaging and detection of Prostate-Specific Membrane Antigen (PSMA) receptor positive malignant lesions

Dazucorilant: Treatment of Amyotrophic Lateral Sclerosis (ALS)

Divarasib: Antineoplastic  

Emirodatamab: Treatment of acute myeloid leukemia (AML)

Fipaxalparant: Treatment of systemic sclerosis (SSc)

Masofaniten: Treatment of prostate cancer

Mavodelpar: Treatment of fatty acid oxidation disorders

Mevafilcon A: Contact lens material

Mitiperstat: Treatment of heart failure

Paltimatrectinib: Antineoplastic

Quisovalimab: Treatment of Crohn’s disease, prevention of ARDS in patients with COVID-19

Tivanisiran: Treatment of dry eye disease

Unasnemab: Treatment of spinal cord injury

Zanzalintinib: Treatment of solid tumors

Zosurabalpin: Treatment of bacterial infections